CORONA Remedies logo

CORONA Remedies financials: balance sheet, profit and loss, cash flow

NSE: CORONABSE: 544644Pharmaceuticals & BiotechnologySmall Cap

CORONA Remedies Limited · Face value ₹10 · Listed Dec 2025 · Issue price ₹1,062
Last close ₹2,149.60down ₹67.80 (3.06%)BSE ₹2,146.05

Share price at the NSE close on 30 Oct 2026. Previous close ₹2,217.40.

30 Oct: open ₹2,217.40, high ₹2,237.40, low ₹2,090.00

Range of traded prices from listing on 15 Dec 2025 to 30 Oct 2026
₹1,336.60Low, 23 Dec 2025₹2,292.40High, 15 Sep 2026
Market cap
₹13,147 Cr566th largest listed
P/E
63.51
P/B
16.33
Dividend yield
0.47%
ROE
28.3%
ROCE
31.8%
Debt to equity
0.12
Volume, NSE
23,61838.1% delivered

CORONA Remedies' financial statements for the year to Mar 2026, consolidated: the company and its subsidiaries together, with the half year to Sep 2026 after them.

1 year at a glance

₹ crore, years to March.CORONA Remedies annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings
1,403185143Mar 26

Operating and net margin, per cent

  • Operating margin
  • Net margin
20.9%13.2%20.9%13.2%Mar 26

Results for the year to Mar 2026

Consolidated: the company and its subsidiaries together. ₹ crore.

From revenue to net profit

  1. Revenue1,403
  2. Materials and goods−261
  3. Employee costs−403
  4. Other expenses−446
  5. Operating profit293
  6. Depreciation−38
  7. Other income+11
  8. One-off items−19
  9. Finance costs−7.0
  10. Profit before tax240
  11. Tax−55
  12. Net profit185

What the company owns

  • Plant, investments and other assets₹890 Cr
  • Receivables₹146 Cr
  • Inventory₹125 Cr
  • Cash and bank₹44 Cr

What pays for it: net worth and liabilities

  • Net worth₹747 Cr
  • Other liabilities₹168 Cr
  • Owed to suppliers₹147 Cr
  • Borrowings₹143 Cr

Profit and loss

Consolidated, ₹ crore, years to March. The last column is the twelve months to Sep 2026, the latest four quarters added.CORONA Remedies quarterly results

₹ croreMar 2026Sep 2026Twelve monthsFiled 30 Oct
Revenue from operations1,4031,559
1,1101,225
Materials and goods bought261285
Employee costs403449
Other expenses446491
Operating profit before depreciation293334
Operating margin20.9%21.4%
Materials, % of revenue18.6%18.3%
Employee costs, % of revenue28.7%28.8%
Other expenses, % of revenue31.8%31.5%
Depreciation and amortisation3848
Operating profit after depreciation256286
Other income1112
Finance costs78
Profit before one-off items and tax259290
One-off items−19−19
Profit before tax240271
5564
Net profit185207
Other comprehensive income00
Total comprehensive income185207
Net margin13.2%13.3%

Balance sheet

Consolidated, ₹ crore, at 31 March. The last column is the half year to Sep 2026, after the latest full year: the balance sheet at its end.

₹ croreMar 2026Sep 2026Half yearFiled 30 Oct
747805
Share capital6161
Reserves686744
14395
361333
97109
Total assets1,2051,247
857773
348474
Net debt99−4
Borrowings are counted again inside the liabilities due within a year and after a year. Plant in use and plant being built are given for full years only.

Cash flow

Consolidated, ₹ crore, years to March. The last column is the half year to Sep 2026, after the latest full year: the cash flow over its six months.

₹ croreMar 2026Sep 2026Half year
229113
279146
−6−43
Receivables−26−25
Inventories5−46
Payables425
Other working capital112
Tax paid−49−34
Capital spending17426
Free cash flow5586
−2563
25−116
Dividends paid061
Shares bought back00
Shares issued00
Net change in cash−10
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only.

Per share

Consolidated, ₹ per share, years to March.CORONA Remedies dividend history

₹ per shareMar 2026
Earnings per share₹30.27
Diluted earnings per share₹30.27
Dividend per share₹10.00
Book value per share₹122.12
Dividend payout33.0%
Shareholder yield0.0%
Market cap at the year end (₹ crore)9,517

Ratios

Consolidated, years to March.CORONA Remedies PE ratio and valuation

RatioMar 2026
Return on equity24.8%
Return on capital employed28.7%
Cash conversion124.0%
Interest cover36.7
Debt to equity0.19
Receivable days38
Inventory days175
Payable days206
Cash conversion cycle, days7
Working capital days22
Asset turnover1.16
Assets per rupee of net worth1.61
Sales per rupee of plant4.82
Capital spending to depreciation4.60
Plant being built, % of plant in use49.2%

Growth and returns over 3, 5 and 10 years

Consolidated: the company and its subsidiaries together. Each window ends with the year to Mar 2026.

Return on assets, latest year
15.4%
Cash from operations against operating profit
78.2%

Where the cash came from and went

Consolidated: the company and its subsidiaries together. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ croreLatest year
Cash from operations229
Cash from investing−256
Cash from financing25
Capital spending174
Dividends paid0
Shares bought back0
Shares issued for cash0
Borrowings raised116
Borrowings repaid36

Accounting checks

Consolidated, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2026
Altman Z-scorePublished threshold 1.8115.08
Effective tax ratePublished threshold 17.16 per cent23.00
Tax charged less tax paid, % of profitOur threshold 10 percentage points2.45
A threshold marked as ours has no published figure; it is the line we read the check against.

Credit ratings

An agency's view of the chance the company repays a borrowing on time, from AAA, the highest, down to D, in default.

DateAgencyBorrowing ratedRatingOutlookAmount, ₹ Cr
9 Oct 2026CARE Ratings LimitedFund-based - LT-Term LoanLong-term scaleCARE A+Review, Re-affirmStable7
9 Oct 2026CARE Ratings LimitedFund-based/Non-fund-based-LT/STLong and short-term scalesCARE A+ / CARE A1+Review, UpgradeLT rating reaffirmedStable70
The latest rating on each borrowing. The agency's name opens its reasoning for the rating.